At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
3TCdrug
Likely dose
3TC 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease (ART-AD)
The University of Texas Health Science Center at San Antonio·interventional·Posted Sep 17, 2020·Updated Aug 9, 2024
In Brief
A Phase 2 clinical trial evaluating 3TC for Alzheimer Disease, Early Onset. Completed, enrolled 12 participants across 3 sites.
Detailed Summary
The objective of the study is to evaluate the ability of (-)-L-2',3'-dideoxy-3'-thiacytidine (3TC) to engage its intended target, penetrate the central nervous system (CNS), suppress neurodegeneration, and assess safety and tolerability in patients with early stage Alzheimer's disease. This study will provide the initial data on target engagement and Alzheimer's disease-relevant outcomes for future trials.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Early Onset
CountriesUnited States
CollaboratorsOwens Medical Research Foundation
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartFeb 2021
Primary CompletionMay 2023
Study CompletionNov 2023
TodayJul 2026
First PostedSep 17, 2020
Enrollment StartFeb 15, 2021
Primary CompletionMay 4, 2023
Study CompletionNov 4, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.8 years ago
Interventions
3TCdrug
12 subjects will be administered 3TC, 300mg once daily, via an oral tablet for 24 weeks.